Navigation Links
Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
Date:6/27/2011

SAN DIEGO, June 27, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer. The publication is now available on the Anti-Cancer Drugs website and scheduled to print in the August issue of the journal.

The studies, conducted in collaboration with lead author Ewan Tytler, Ph.D., at the University of Alabama at Birmingham Medical Center and the Yale University School of Medicine, detail the in vitro activity of Triphendiol in pancreatic cancer cells as well as its in vivo activity in animal models of pancreatic cancer. In addition, both studies show that pre-treatment with Triphendiol enhances the cytotoxic effect of gemcitabine, the standard-of-care chemotherapy currently used to treat advanced pancreatic cancer. An abstract of the publication, entitled "Triphendiol (NV-196), Development of a Novel Therapy for Pancreatic Cancer," can be found at www.marshalledwardsinc.com/our-programs/scientific-publications.

In previous laboratory studies, Triphendiol demonstrated anti-cancer activity against a broad range of tumor cell lines, including breast, colorectal and ovarian. Once administered, Triphendiol is converted in vivo into an active metabolite called NV-143. In addition to being more active than Triphendiol as a single agent, NV-143 appears to be superior in its ability to synergize with chemotherapy in pre-clinical studies. Marshall Edwards has completed the required pre-clinical studies of NV-143 necessary to complete an Investigational New Drug application, which it plans to submit to the U.S. Food and Drug Administration next month.

"These studies add to our growing collection of data regarding the activity of our compounds and their potential ability to enhance the effects of current treatments," said Robert D. Mass, MD, Chief Medical Officer of Marshall Edwards. "These data further support the clinical development strategy for our lead candidate NV-143, the primary metabolite of Triphendiol, in combination with standard-of-care chemotherapy, while expanding the potential drug combinations we can consider in our randomized Phase II clinical trials."

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes Triphendiol and lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
2. Marshall Edwards Announces Private Placement
3. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
4. Marshall Edwards Receives Positive Response From NASDAQ
5. Marshall Edwards to Host Annual Meeting of Stockholders
6. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
7. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
8. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
9. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
10. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
11. Curaxis Pharmaceutical Corporation Announces Key Changes to Its Board of Directors and Management Team in Progression Toward Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of the ... based on extensive data analysis from GHI,s hospitals database ... database for the region. The GHI database covers 86% of ... more than 130 data points for each institution in key ...
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
Breaking Medicine Technology:
(Date:5/21/2017)... (PRWEB) , ... May 21, 2017 , ... ... if it's been longer than six months since you've seen a dentist, it's ... twice per year and getting x-rays once per year. , Dental checkups are ...
(Date:5/19/2017)... ... May 19, 2017 , ... When Kyle Busch graduates from ... will already appear on two major research studies that could impact the health of ... Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside an international team trying to ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Arnold ... Young Investigators: , Victor Acosta, Ph.D. - University of New Mexico, Jeremy Baskin, ... - University of Washington, Erik Grumstrup, Ph.D. - Montana Stata University, A. Fatih ...
(Date:5/19/2017)... ... 2017 , ... CloSYS products which are marketed as the gentle giants of ... and gum health, which is linked to one’s overall health. Since 1991 when the ... powerful ways in which CloSYS products immediately helped eliminate bad breath as well as ...
(Date:5/18/2017)... ... ... Originally launched to market as the EPIK Learning Tab, the highly successful ... of their product line, the company believed it was the right time to create ... be any tablet product sold by EPIK Learning. This year there will be ...
Breaking Medicine News(10 mins):